Monoclonal antibodies against human thyroglobulin were produced by the hybridoma technique. Using three non-crossreactive monoclonal antibodies, an IRMA system was developed, with a polyclonal rabbit antibody fixed on microtiter plates as first extracting antibody. The monoclonal antibodies were used as second antibody, while anti-mouse IgG-biotin from goat and [ I25 l]streptavidin served as the indicator system. The source of the monoclonal antibodies was diluted culture medium without purification. Sensitivities of 3-4 g/l were obtained with all 3 monoclonal antibodies; interassay variation was about 5%. This test system will be used for further immunological characterization of circulating thyroglobulin in different thyroid diseases.
Introduction
dence that tumour thyroglobulin is different from ™ ,· . t · · · thyroglobulin of the normal thyroid gland (2 -6) . To Thyroglobulin is the most characteristic protein of .
., ., , , v . . . ·«.·*!. r , , ., t J T i, .. . . , , improve the thyroglobulin test system it is therefore the thyroid gland. In small quantities it is regularly .
. . . , r r , . ' . . . -~ . -.' : . -. , t · important to clarify whether there is a particular found in the circulation but the exact mechanism , "f .. r · . i u r ju^u , . , , , t -, .
, . heterogeneity of tumour thyroglobulin and whether which leads to the appearance of this compound in -. . r .. -' . , , -5ii , r«, , , v , this is of diagnostic importance, the blood stream is still unclear. Thyroglobulin has a molecular weight of about 660 000 and is composed We have developed an immunoradiometric system for of two polypeptide chains and a carbohydrate moiety the measurement of serum thyroglobulin which can of about 10% of the molecular weight (1) . Micro-use different non-crossreactive monoclonal antibodies heterogeneity of thyroglobulin is a well-known phe-against thyroglobulin. nomenon; it might be partly due to different extents of iodination of the subunits and variations of the ^. I by the chloramine Τ method as described previously (7) . The iodinated monoclonals were used in cross inhibition experiments.
General design of the immunoradiometric assay
Microtitre plates were coated with 50 μΐ rabbit anti-human thyroglobulin IgG in carbonate buffer, pH 10.6, 0.2 mol/1 for 20 h at 4 °C. This was followed by a blocking step to absorb unoccupied binding sites (10 g/1 gelatin for 1 h). After washing 3 times with phosphate buffered saline, thyroglobulin standards or unknown samples (50 μΐ) were incubated for 2 h at room temperature. After another washing step (3 times phosphate buffered saline) monoclonal antibody was incubated for 1 h. This was followed by a further wash (3 times phosphate buffered saline) and incubation with goat anti-mouse IgG-biotin. There was no crossreaction of the anti-mouse IgG-biotin with the coated rabbit IgG. Finally, after intensive washing (4 times phosphate buffered saline), [ 125 I]labeled streptavidin was applied for 1 h. After a final washing step (3 times phosphate buffered saline), the wells were counted in a gamma counter. All phosphate buffered saline solutions for washing contained 5 ml/1 Tween 20.
Results
Using cross blocking experiments, we selected 3 monoclonal antibodies, specific for 3 different antigenie epitopes. An example of such experiments is shown in figure 1 for labeled antibodies Tg 11 and Tg 13. Both antibodies were purified by protein A sepharose and labeled by the chloramine T method. As demonstrated, binding of labeled Tg 11 was inhibited by antibodies 48, 46, 62, 67, whereas antibody 13 showed no crossreaction with these antibodies. For further studies the non-crossreacting antibodies Tg 11, Tg 13 and Tg 40 were chosen; the affinity constants of the three antibodies, calculated by the method of Mw/fer(8),werel.02 χ ΙΟ 10 1/mol (Tg 11), 3.2 χ ΙΟ 10 1/mol (Tg 13) and 1.15 χ ΙΟ 9 1/mol (Tg 40); all antibodies were of the IgG2 class. Figure 2 shows the results obtained by varying the coating (first) antibody. Three thyroglobulin concentrations in buffer were used and the procedure was performed as described in the section on materials x-1:4000; Δ -1:8000) followed by incubation with 3 concentrations of human thyroglobulin (10,100,1000 μg/l); second antibody: Tg 13 (1:10); finally, goat antimouse IgG-biotin as described under "Methods".
and methods. The second antibody in this case was Tg 13, and after incubation with anti-mouse IgGbiotin, radioactive streptavidin was counted. The optimal titre of the coating antibody was about 1:2000; this titre was used in further experiments. Figure 3 shows the test results obtained with variations of the monoclonal antibody, in this case Tg 13. It is obvious that the supernatant of the clone Tg 13 contains antibody in excess, and we decided to use a 1:10 dilution of this particular supernatant. It seems important to determine the optimal concentrations for each monoclonal antibody, ΐρ* avoid results that contain unnecessarily high levels of unspecific binding. Finally we investigated the effect of different amounts of biotin-labeled anti-mouse IgG in this system. figure 5 , increasing the titre from 1:1000 to 1:500 results in an disproportionate increase of nonspecific binding. This means that most of the increasing counts observed with high concentrations of anti-mouse IgG-biotin are due to nonspecific binding. Most of this nonspecific binding seems to be due to some residual cross-reactivity of the anti-mouse IgG with the coated rabbit anti human thyroglobulin IgG. The optimal concentration of antimouse IgG-biotin is in the titre range of 1:1000 to 1:2000. Figure 4 and 5 demonstrate that a compromise has to be accepted between optimal specific binding and minimal nonspecific binding. We chose a titre of 1:1000 because the nonspecific binding of 2000 counts/min seemed reasonable in comparison to the steepness of the curve. However, it might turn out that conditions with lower nonspecific binding might be preferential, especially in the lower thyroglobulin concentration range. It becomes evident from this experiment that anti-mouse IgG-biotin is one of the limiting factors in this system, and that it is impossible to use this reagent in excess. Table 1 summarized the exact conditions of the IRMA worked out by the demonstrated experiments, and figure 6 shows standard curves of 3 different assays with 3 different monoclonal antibodies in serum standards. The levelling off in the high concentration range, which is usually not seen in conventional IRMA systems, is due to the above-mentioned limitation on the amount of anti-mouse IgG-biotin which can be used in this system. In table 2 some statistical data of these three assay systems are summarized. The sensitivity (three standard deviations at zero point) and the intra-and inter-assay variations (at 50 μ §/1) are similar in all 3 systems and seem comparable with those of most polyclonal assays. Thyroglobulin is a very complex macroinolecule and it is still unproven whether the use of monoclonal antibodies will be of advantage in the radioimmunological determination of serum thyroglobulin. In particular, the possibility of tumour-specific variants of antigenic epitopes of thyroglobulin might be a problem (3, 4, 6, 8) . On the other hand, it might be possible to develop a thyroglobulin test system which is not influenced by autoantibodies, because the epitope specificity of autoantibodies seems to be very limited (9) .
We describe an IRMA system for thyroglobulin meas^· urement in serum which uses a polyclonal rabbit antibody as first extracting antibody and mouse monoclonal antibody as second. The second antibody consists of diluted culture medium of specific unlabelled clones. A biotin-labeled anti-mouse IgG (goat) and [
125 I]labeled avidin serve as indicators. Thus the monoclonal antibodies can easily be exchanged for different epitope specificity. By the systematic use of different non cross-reacting monoclonal antibodies we are now able to investigate the preservation or deletion of various antigenic epitopes of serum thyroglobulin in thyroid cancer patients. By this sensitive device we will be able to clarify whether the postulated increased immunological heterogeneity of tumour thyroglobulin really exists and, if so, whether it is of diagnostic significance. In general, it will be possible to investigate whether thyroglobulin species specific for thyroid disease can be found in the circulation.
